Get the Stockscreener App
62.32
0.99%
-0.62
After Hours:
62.90
0.58
+0.93%
Crispr Therapeutics Ag stock is traded at $62.32, with a volume of 5.23M.
It is down -0.99% in the last 24 hours and up +15.07% over the past month.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
See More
Previous Close:
$62.94
Open:
$63.18
24h Volume:
5.23M
Relative Volume:
1.65
Market Cap:
$5.67B
Revenue:
$170.10M
Net Income/Loss:
$-239.59M
P/E Ratio:
-22.26
EPS:
-2.8
Net Cash Flow:
$-191.20M
1W Performance:
+10.77%
1M Performance:
+15.07%
6M Performance:
+48.59%
1Y Performance:
+25.92%
1-Day Range:
$62.27
$64.18
1-Week Range:
$55.68
$64.18
52-Week Range:
$30.04
$71.13
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Name
Crispr Therapeutics Ag
Sector
Industry
Phone
(617) 315-4600
Address
BAARERSTRASSE 14, ZUG
Compare CRSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
62.32 | 5.72B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | JP Morgan | Overweight |
| Feb-14-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-12-25 | Upgrade | TD Cowen | Sell → Hold |
| Feb-03-25 | Initiated | H.C. Wainwright | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| Aug-02-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | Guggenheim | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-27-23 | Initiated | Mizuho | Buy |
| Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
| May-30-23 | Initiated | William Blair | Outperform |
| Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Mar-07-23 | Initiated | Robert W. Baird | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
| Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
| Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-10-20 | Reiterated | Needham | Buy |
| Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Jul-28-20 | Reiterated | Needham | Buy |
| Jul-14-20 | Initiated | SunTrust | Buy |
| Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-01-19 | Initiated | Jefferies | Buy |
| Jul-26-19 | Initiated | Canaccord Genuity | Buy |
| Jun-10-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-14-19 | Initiated | William Blair | Mkt Perform |
| Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
Crispr Therapeutics Ag Stock (CRSP) Latest News
Crispr Therapeutics AG Surges Amid Analyst Praise - TipRanks
Hedges Asset Management LLC Has $1.20 Million Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG $CRSP Shares Sold by Goldman Sachs Group Inc. - MarketBeat
CRISPR Therapeutics (CRSP) Jumps 9.6% on Biotech Rally - MSN
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 1,262,560 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
First Week of November 21st Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq
Jobs Data: Does CRISPR Therapeutics AG have pricing powerWeekly Gains Report & Reliable Price Breakout Signals - khodrobank.com
JPMorgan Chase & Co. Initiates Coverage on CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
Aug Action: Is CRISPR Therapeutics AG stock good for income investors2025 Trading Volume Trends & Real-Time Sentiment Analysis - khodrobank.com
Patterns Watch: What is the long term forecast for CRISPR Therapeutics AG stock2025 Institutional Moves & Real-Time Market Sentiment Alerts - khodrobank.com
Hedge Fund Bets: Why is CRISPR Therapeutics AG stock going downWeekly Loss Report & Reliable Volume Spike Alerts - khodrobank.com
Millennium Management LLC Buys 575,235 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years - Benzinga
CRISPR Therapeutics (CRSP) Gains on J.P. Morgan's Overweight Rat - GuruFocus
CRISPR Therapeutics wins new Overweight rating at J.P. Morgan on pipeline prospects - MSN
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises - Benzinga
JP Morgan Initiates Coverage of CRISPR Therapeutics (CRSP) with Overweight Recommendation - Nasdaq
CRSP: JP Morgan Initiates Coverage with Overweight Rating | CRSP Stock News - GuruFocus
Crispr Therapeutics AG: Promising Growth and Strategic Opportunities Justify Buy Rating - TipRanks
CRISPR Therapeutics stock initiated with Overweight rating by JPMorgan - Investing.com India
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - sharewise.com
Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track (CRSP) - Seeking Alpha
CRISPR (CRSP) Gains Analyst Support on Sales Momentum and Pipeline Expansion - MSN
Gene Editing Market Exclusive Report with Detailed Study & - openPR.com
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 6.8%Here's Why - MarketBeat
Momentum Shift: Will CRISPR Therapeutics AG stock hit new highs in YEARLayoff News & Community Supported Trade Ideas - خودرو بانک
Aug Final Week: Is CRISPR Therapeutics AG a speculative investmentJuly 2025 News Drivers & Stepwise Entry and Exit Trade Signals - خودرو بانک
Aug Closing: Is CRISPR Therapeutics AG still a buy after recent gainsJuly 2025 Drop Watch & AI Enhanced Execution Alerts - خودرو بانک
Earnings Report: Is LIQT forming a breakout patternInsider Selling & Fast Gaining Stock Strategy Reports - خودرو بانک
Genome Editing Market Forecast Report 2025-2030, with Profiles of Merck, Horizon Discovery, GenScript, Sangamo Therapeutics, Danaher, Lonza, BEX, OriGene Technologies, CRISPR Therapeutics, and More - uk.finance.yahoo.com
12,424 Shares in CRISPR Therapeutics AG $CRSP Acquired by Bayforest Capital Ltd - MarketBeat
Earnings Report: Can CRISPR Therapeutics AG stock outperform in a bear market2025 Price Action Summary & Advanced Swing Trade Entry Alerts - khodrobank.com
Investment Recap: Will CRISPR Therapeutics AG benefit from government policyWeekly Loss Report & Weekly Chart Analysis and Trade Guides - خودرو بانک
Institution Moves: What is the long term forecast for CRISPR Therapeutics AG stockJuly 2025 Price Swings & Safe Swing Trade Setups - khodrobank.com
Tech Rally: Is CRISPR Therapeutics AG showing insider buyingGold Moves & Free Expert Verified Stock Movement Alerts - khodrobank.com
What CRISPR Therapeutics (CRSP)'s Pipeline Updates and Casgevy Adoption Mean for Shareholders - simplywall.st
Loss Report: Is CRISPR Therapeutics AG a speculative investmentIndex Update & Real-Time Market Sentiment Alerts - خودرو بانک
CRISPR Therapeutics (CRSP): Revisiting Valuation in Light of New Clinical Data and Expanding Commercial Momentum - Yahoo Finance
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - sharewise.com
CRISPR Therapeutics AG $CRSP Position Raised by Raymond James Financial Inc. - MarketBeat
Trexquant Investment LP Acquires Shares of 38,831 CRISPR Therapeutics AG $CRSP - MarketBeat
Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest? - sharewise.com
CRISPR Therapeutics AG (CRSP)’s Casgevy Expands Global Adoption in 2025 - MSN
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - sharewise.com
Crispr Therapeutics Ag Stock (CRSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):